These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24267389)

  • 1. Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later.
    Weiner DE; Winkelmayer WC
    Am J Kidney Dis; 2013 Dec; 62(6):1217-20. PubMed ID: 24267389
    [No Abstract]   [Full Text] [Related]  

  • 2. The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle.
    Fuller DS; Pisoni RL; Bieber BA; Port FK; Robinson BM
    Am J Kidney Dis; 2013 Dec; 62(6):1213-6. PubMed ID: 24140369
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic considerations in a changing anemia environment.
    Pizzi LT
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
    Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
    Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 6. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
    Wish JB
    Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rebates for anti-anemia drugs draw response from FDA, CMS.
    Sipkoff M
    Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
    [No Abstract]   [Full Text] [Related]  

  • 8. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
    Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care.
    Wetmore JB; Tzivelekis S; Collins AJ; Solid CA
    BMC Nephrol; 2016 May; 17(1):53. PubMed ID: 27228981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients.
    Ofsthun NJ; Lazarus JM
    Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. It's time to financially incentivize vascular access management.
    Neumann ME
    Nephrol News Issues; 2014 Apr; 28(4):8. PubMed ID: 24960981
    [No Abstract]   [Full Text] [Related]  

  • 13. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS).
    Brunelli SM; Monda KL; Burkart JM; Gitlin M; Neumann PJ; Park GS; Symonian-Silver M; Yue S; Bradbury BD; Rubin RJ
    Am J Kidney Dis; 2013 Jun; 61(6):947-56. PubMed ID: 23332991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DOPPS Practice Monitor for US dialysis care: trends through August 2011.
    Pisoni RL; Fuller DS; Bieber BA; Gillespie BW; Robinson BM
    Am J Kidney Dis; 2012 Jul; 60(1):160-5. PubMed ID: 22560744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98.
    Greer JW; Milam RA; Eggers PW
    Health Care Financ Rev; 1999; 20(3):55-62. PubMed ID: 10558020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The primary care group model.
    Gastright JA
    J Med Assoc Ga; 1994 Oct; 83(10):569-72. PubMed ID: 7989892
    [No Abstract]   [Full Text] [Related]  

  • 17. Projected impact of the proposed "bundled" ESRD payment system on a small dialysis organization.
    Bhat P; Sokolowski W; Bhat JG
    Nephrol News Issues; 2009 Jun; 23(7):46, 48-52. PubMed ID: 19585810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The changing tide in ESRD care.
    Sullivan JD
    Nephrol News Issues; 2010 Jul; 24(8):24, 27-8. PubMed ID: 20695319
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoietin claims monitoring policy: implications for clinical practice.
    Messana T
    Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
    Messana T
    Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.